Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.
Tali Azenkot, MD
Advertisement
Tali Azenkot, MD, is a fellow of hematology and oncology at the University of California San Diego Health.
Articles by Tali Azenkot, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
4
Phosphorus-32 Plus FOLFIRINOX Meets Primary End Points in Locally Advanced Pancreatic Cancer
5